glp 1 and fragrance GLP-1 Users Are Developing Unexpected Perfume Obsessions 2025Q3 FDA says no to Pump:No Designed to help manage

glp 1 and fragrance GLP-1 Users Are Developing Unexpected Perfume Obsessions 2025Q3 FDA says no to Pump:No Designed to help manage

FDA says no to Lilly, Boehringer's Jardiance in type 1 diabetes - PMLiVE

However, beyond just helping with blood sugar and weight, studies have shown these medications may offer significant benefits for heart health in those who have cardiovascular disease and obesity

2025Q3

Pump:No

The process has three levels: Level 1: Standard appeal (provider-initiated) Your prescriber submits additional clinical documentation supporting medical necessity Timeline: OptumRx must respond within 30 calendar days for standard appeals, 72 hours for expedited appeals Success rate: approximately 40% when new documentation is provided Common successful arguments: updated BMI documentation, additional comorbidity diagnosis, documented contraindication to step therapy medication Level 2: External review (patient or provider-initiated) If Level 1 is denied, you can request an independent external review by a third-party clinical reviewer not employed by OptumRx Timeline: 60 days for standard, 72 hours for expedited Success rate: approximately 25% The external reviewer evaluates whether the denial was consistent with standard medical practice Level 3: State insurance commissioner complaint If external review is denied, you can file a complaint with your state insurance department Timeline: varies by state (30 to 90 days) Success rate: low (under 15%), but occasionally results in policy changes for future patients When appeals are most likely to succeed: New diagnosis of comorbidity

Designed to help manage daily cravings and promote mindful habits